Jabil Work in process increased by 11.7% to $306.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.9%, from $312.00M to $306.00M. Over 5 years (FY 2020 to FY 2025), Work in process shows a downward trend with a -5.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $646.13M | $677.00M | $552.00M | $628.00M | $699.00M | $687.00M | $546.00M | $499.00M | $472.00M | $217.00M | $241.00M | $232.00M | $197.00M | $190.00M | $245.00M | $312.00M | $326.00M | $335.00M | $274.00M | $306.00M |
| QoQ Change | — | +4.8% | -18.5% | +13.8% | +11.3% | -1.7% | -20.5% | -8.6% | -5.4% | -54.0% | +11.1% | -3.7% | -15.1% | -3.6% | +28.9% | +27.3% | +4.5% | +2.8% | -18.2% | +11.7% |
| YoY Change | — | — | — | — | +8.2% | +1.5% | -1.1% | -20.5% | -32.5% | -68.4% | -55.9% | -53.5% | -58.3% | -12.4% | +1.7% | +34.5% | +65.5% | +76.3% | +11.8% | -1.9% |
| % of Inventories | 16.2% | 15.3% | 11.8% | 11.6% | 11.7% | 11.2% | 8.5% | 7.7% | 7.8% | 4.2% | 4.7% | 4.8% | 4.4% | 4.4% | 5.7% | 7.0% | 6.8% | 7.2% | 5.9% | 6.2% |
| Share Change | — | -0.9pp | -3.5pp | -0.2pp | +0.0pp | -0.5pp | -2.7pp | -0.8pp | +0.1pp | -3.6pp | +0.5pp | +0.1pp | -0.4pp | +0.0pp | +1.2pp | +1.4pp | -0.2pp | +0.3pp | -1.3pp | +0.3pp |